Divyang Patel

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary

International Union of Basic and Clinical Pharmacology. XCV. Recent Advances in the Understanding of the Pharmacology and Biological Roles of Relaxin Family Peptide Receptors 1–4, the Receptors for Relaxin Family Peptides

Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation

Trends in GPCR drug discovery: new agents, targets and indications

Physiological changes in pregnancy

The renal circulation in normal pregnancy and preeclampsia: is there a place for relaxin?

2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation

Mechanistic Features Associated With Improvement in Mitral Regurgitation After Cardiac Resynchronization Therapy and Their Relation to Long-Term Patient Outcome

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation

Relaxin Suppresses Atrial Fibrillation by Reversing Fibrosis and Myocyte Hypertrophy and Increasing Conduction Velocity and Sodium Current in Spontaneously Hypertensive Rat Hearts

Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation

The magnitude of reverse remodelling irrespective of aetiology predicts outcome of heart failure patients treated with cardiac resynchronization therapy